August 24, 2016

Companion Diagnostics

Extensive expertise to accelerate your tandem development pathway
The market landscape is changing as an enhanced understanding of disease biology, the introduction of new clinical trial protocols, next-generation sequencing, reimbursement constraints, immunotherapy treatments and changing regulatory guidelines impact the progress of companion diagnostics. Conflicting demands on the system make it difficult to assess the best way to move forward.

Q2 Solutions can help you simplify and align co-development strategies to speed companion diagnostic development and increase the probability of regulatory and commercial success.

Download this factsheet to learn how our deep understanding of clinical development, diagnostic development, regulatory requirements and strategic partnership models, can help you achieve better outcomes.

From eligibility to CDx: developing and implementing effective biomarker strategies for Immuno-oncology trials

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Read More